The U.S. antimicrobial catheters market size was estimated at USD 506.18 million in 2025 and is projected to reach USD 932.44 million by 2033, growing at a CAGR of 7.94% from 2026 to 2033. The growth of this market is primarily driven by the rising incidence of hospital-acquired infections, the increasing number of catheterization procedures across acute and long-term care settings, and the growing clinical focus on infection prevention and patient safety.
More than 1 million cardiac catheterization procedures are performed every year in the U.S. In addition, expanding adoption of antimicrobial-coated devices, supportive infection control guidelines, and increasing healthcare investments in advanced medical technologies are further supporting market expansion.
CLABSI (central line-associated bloodstream infections), CAUTI (catheter-associated urinary tract infections), and VAE (ventilator-associated events) are major drivers of the U.S. antimicrobial catheters market. They represent the primary hospital-acquired infection (HAI) burden, increasing clinical and economic pressure on healthcare systems to adopt infection-prevention technologies. High incidence of these device-associated infections leads hospitals to prioritize antimicrobial-coated and drug-eluting catheter technologies to reduce microbial colonization and infection risk. Studies show that antimicrobial-coated catheters can reduce microbial colonization, which directly supports hospital infection reduction programs and procurement shifts toward coated devices. In addition, the broader rise in HAIs has led hospitals to increasingly standardize the use of coated catheters as part of infection control protocols, reinforcing demand for antimicrobial catheter products across ICU, surgical, and long-term care settings.
This product will be delivered within 1-3 business days.
More than 1 million cardiac catheterization procedures are performed every year in the U.S. In addition, expanding adoption of antimicrobial-coated devices, supportive infection control guidelines, and increasing healthcare investments in advanced medical technologies are further supporting market expansion.
CLABSI (central line-associated bloodstream infections), CAUTI (catheter-associated urinary tract infections), and VAE (ventilator-associated events) are major drivers of the U.S. antimicrobial catheters market. They represent the primary hospital-acquired infection (HAI) burden, increasing clinical and economic pressure on healthcare systems to adopt infection-prevention technologies. High incidence of these device-associated infections leads hospitals to prioritize antimicrobial-coated and drug-eluting catheter technologies to reduce microbial colonization and infection risk. Studies show that antimicrobial-coated catheters can reduce microbial colonization, which directly supports hospital infection reduction programs and procurement shifts toward coated devices. In addition, the broader rise in HAIs has led hospitals to increasingly standardize the use of coated catheters as part of infection control protocols, reinforcing demand for antimicrobial catheter products across ICU, surgical, and long-term care settings.
U.S. Antimicrobial Catheters Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. antimicrobial catheters market report on the basis of product type, technology, material, and end use:Product Type Outlook (Revenue, USD Million, 2021-2033)
- Urological Catheters
- Vascular Access Catheters
- Specialty and Surgical Catheters
Technology Outlook (Revenue, USD Million, 2021-2033)
- Silver-Based Technology
- Antibiotic-Impregnated
- Organic/Polymer-Based (Non-Metal/Non-Antibiotic)
- Combination Technologies
Material Outlook (Revenue, USD Million, 2021-2033)
- Silicone
- Polyurethane (PU)
- Latex
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Ambulatory Surgical Centers (ASCs)
- Long-Term Care Facilities (LTCs)
- Home Care
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Antimicrobial Catheters Market Variables, Trends & Scope
Chapter 4. U.S. Antimicrobial Catheters Market: Product Type Estimates & Trend Analysis
Chapter 5. U.S. Antimicrobial Catheters Market: Technology Estimates & Trend Analysis
Chapter 6. U.S. Antimicrobial Catheters Market: Material Estimates & Trend Analysis
Chapter 7. U.S. Antimicrobial Catheters Market: End Use Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- B. Braun SE
- Teleflex Incorporated
- SilvoGuard
- BD
- MEDLINE
- ConvaTec Group PLC
- Silq Technologies
- AvantGuard (Halomine Inc.)
- Medtronic
- Cook
- Integra LifeSciences Corporation
- Vygon
- Camstent
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | March 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 506.18 Million |
| Forecasted Market Value ( USD | $ 932.44 Million |
| Compound Annual Growth Rate | 7.9% |
| Regions Covered | United States |
| No. of Companies Mentioned | 13 |
